Evidence map›Paper›PMID 26203771›Full record

ArticleOncotarget2015

The downregulation of ΔNp63 in p53-deficient mouse epidermal tumors favors metastatic behavior.

Olga Bornachea, Fernando F López-Calderón, Marta Dueñas, Carmen Segrelles, Corina Lorz, Cristian Suárez-Cabrera, María Marañón, Beatriz Paradela-Dobarro, Mirentxu Santos, Jesús M Paramio

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. p63 Is a Promising Marker in the Diagnosis of Unusual Skin Cancer.International journal of molecular sciences · 2019
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Olga BornacheaMolecular Oncology Unit, CIEMAT, 28040 Madrid, Spain.
Fernando F López-CalderónMolecular Oncology Unit, CIEMAT, 28040 Madrid, Spain.
Marta DueñasMolecular Oncology Unit, CIEMAT, 28040 Madrid, Spain.
Carmen SegrellesMolecular Oncology Unit, CIEMAT, 28040 Madrid, Spain.
Corina LorzMolecular Oncology Unit, CIEMAT, 28040 Madrid, Spain.
Cristian Suárez-CabreraMolecular Oncology Unit, CIEMAT, 28040 Madrid, Spain.
María MarañónMolecular Oncology Unit, CIEMAT, 28040 Madrid, Spain.
Beatriz Paradela-DobarroMolecular Oncology Unit, CIEMAT, 28040 Madrid, Spain.
Mirentxu SantosMolecular Oncology Unit, CIEMAT, 28040 Madrid, Spain.
Jesús M ParamioMolecular Oncology Unit, CIEMAT, 28040 Madrid, Spain.
Research Institute Hospital 12 de Octubre · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The TP63 gene codes for two major isoform types, TAp63 and ΔNp63, with probable opposite roles in tumorigenesis. The ΔNp63α protein is frequently amplified and overexpressed in different epithelial tumors. Accordingly, it has been considered a potential oncogene. Nonetheless, a possible metastatic suppressor activity has also been suggested based on the experimental observation that its expression is reduced or even absent in advanced invasive tumors. Such metastatic suppressor activities are often related to tumors bearing point mutated TP53 gene. However, its potential roles in TP53-deficient tumors are poorly characterized. Here we show that in spontaneous tumors, induced by the epidermal-specific Trp53 ablation, the reduction of ΔNp63 expression is an early event, whereas it is re-expressed in the lung metastatic lesions. Using knock down and ectopic expression approaches, we show that ΔNp63 expression opposes the epithelial-mesenchymal transition and reduces the metastatic potential of the cells. This process occurs through the modulation of ΔNp63-dependent downstream targets (including transcription factors and microRNAs) likely to play metastatic roles. Further, ΔNp63 also favors the expression of factors involved in iPS reprogramming, thus suggesting that it can also modulate specific stem cell traits in mouse epidermal tumor cells. Overall, our data assign antimetastatic roles to ΔNp63 in the context of p53 deficiency and epidermis.

Indexed as

Down-RegulationAnimalsCell LineEpidermisEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansImmunohistochemistryKeratinocytesMiceMicroscopy, FluorescenceMutationNeoplasm MetastasisPhosphoproteinsPoint MutationSkinPhosphoproteinsTP53 protein, humanTP63 protein, humanTrans-ActivatorsTranscription FactorsTrp63 protein, mouseTumor Suppressor Protein p53Tumor Suppressor ProteinsmetastasismiRNAp53p63skin

Identifiers

PMID26203771
PMCPMC4695182
OpenAlexW2106477431

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.